ITL Health Group (ASX:ITD) is pleased to announce the launch of ITL BioMedical’s latest blood culture testing product, the Transfer Cap Set.
The Transfer Cap Set is a product used to transfer positive culture samples from a bacterial collection bottle to a vacuum tube safely and efficiently. The product is designed for use in hospital laboratories that automate smearing samples from positive bacterial detection bottles.
Continue reading “ITL BioMedical Launches New Blood Culture Testing Product” →
ITL BioMedical, a division of ITL Health Group (ASX:ITD), that creates and manufacturers leading edge medical devices for the clinical, blood banking and laboratory markets, is pleased to announce the launch of a new global brand, ITL Clinical, that will feature ITL products that serve the hospital and clinical markets.
Continue reading “ITL BioMedical Launches “ITL Clinical”, a New Brand to Target Hospital and Clinical Markets” →
Boardroom Media Interview
ITL Health Group (ASX:ITD) is pleased to provide the opportunity to listen to an audio interview with Mr. Bill Mobbs, Executive Chairman.
Continue reading “Audio Interview with Bill Mobbs discussing Strategy and Expectations” →
ITL Health Group (ASX:ITD), an innovative global medical technology company is pleased to announce that Melbourne based Henslow have initiated coverage on ITL Health Group.
Continue reading “Henslow Initiates Research Coverage” →
ITL Health Group (ASX:ITD), an innovative global medical technology company, is pleased to announce the sale of its Australian Custom Pack business unit, part of the ITL Healthcare division, to Nasdaq-listed multi-national Merit Medical Systems, Inc. (“Merit”) for $14.4m (“Sale”). The Sale was signed and completed on 2nd October 2017.
Continue reading “Sale of Custom Pack Business for $14.4 million” →
ITL BioMedical, a division of ITL Health Group (ASX:ITD), that sets industry standards for the innovative design and production of biological sampling systems, is pleased to announce a contract extension of 12 months with a large US community blood bank for its SampLok® Sampling Kit (“SSK”). ITL BioMedical has been a supplier to this blood center for over four years.
Continue reading “ITL Wins SSK Contract Extension with US Blood Bank” →
ITL Health Group (ASX:ITD) is pleased to provide the opportunity to listen to an audio interview with Mr. Bill Mobbs, Executive Chairman, following the release of the Company’s Full Year Results today.
Continue reading “Interview with Bill Mobbs discussing Full Year Results” →
ITL Health Group (ASX:ITD) is pleased to announce financial results for the year ending 30 June 2017 that show considerable year on year profit growth.
Continue reading “ITL Announces Positive 2017 Financial Results” →
ITL Health Group (ASX:ITD), is pleased to announce that its wholly owned subsidiary MyHealthTest Pty Ltd (MHT), the direct to consumer pathology test provider, achieved considerable public interest during National Diabetes Week.
Continue reading “National Diabetes Week Drives Demand for MyHealthTest” →
